| 6.28 0.13 (2.11%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.31 | 1-year : | 10.78 |
| Resists | First : | 7.97 | Second : | 9.23 |
| Pivot price | 6.46  |
|||
| Supports | First : | 5.94 | Second : | 4.94 |
| MAs | MA(5) : | 6.1 |
MA(20) : | 6.73 |
| MA(100) : | 5.99 |
MA(250) : | 4.38 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 7.8 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 9.23 | Low : | 2.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SGHT ] has closed above bottom band by 39.1%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.38 - 6.4 | 6.4 - 6.43 |
| Low: | 6.05 - 6.08 | 6.08 - 6.1 |
| Close: | 6.23 - 6.28 | 6.28 - 6.32 |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Sat, 31 Jan 2026
Sight Sciences (NASDAQ:SGHT) Raised to Strong-Buy at William Blair - MarketBeat
Fri, 30 Jan 2026
William Blair resumes Sight Sciences stock with Outperform rating - Investing.com
Wed, 21 Jan 2026
Sight Sciences (SGHT) chief legal officer sells $41,758 in stock - Investing.com
Wed, 21 Jan 2026
Paul Badawi Sells 22,362 Shares of Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
Wed, 21 Jan 2026
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk - simplywall.st
Wed, 14 Jan 2026
Sight Sciences (SGHT) Price Target Increased by 19.11% to 9.54 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 53 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 20.6 (%) |
| Held by Institutions | 49.6 (%) |
| Shares Short | 983 (K) |
| Shares Short P.Month | 949 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -60.7 % |
| Operating Margin | -25.7 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -58 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 1.23 |
| Sales Per Share | 1.43 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -6.98 |
| PEG Ratio | 0 |
| Price to Book value | 5.1 |
| Price to Sales | 4.36 |
| Price to Cash Flow | -10.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|